Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Actavis shells out $23 per share for Durata; deal valued at $616mm

Executive Summary

In a move that significantly enhances its emerging infectious disease business, specialty pharmaco Actavis PLC is acquiring public Irish firm Durata Therapeutics Inc. for $23.00 in cash per share (a 75% premium), valuing the transaction at $616mm. Actavis will also issue Durata stockholders contingent value rights (CVRs) to receive up to $5.00 per share if certain regulatory and commercial milestones are met for its lead product Dalvance (dalbavancin).

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Earnout
    • Payment Includes Cash

Related Companies